psilocybin

{ "content": "Psilocybin is an indole alkaloid compound, first identified as the active ingredient in magic mushrooms by Albert Hoffman, that shares structural similarities with the neurotransmitter serotonin [fact:9|Albert Hoffman was the first to identify psilocybin...], [fact:22|Psilocybin and psilocin are indole alkaloids found in...]. As a lipophilic compound, it crosses the blood-brain barrier to act as a potent hallucinogen [fact:23|Psilocybin and psilocin are lipophilic compounds, which allows...]. Research indicates that psilocybin affects the brain by destabilizing networks involved in introspection [fact:7|Psilocybin, the active ingredient in magic mushrooms, destabilizes...], initiating hyperconnectivity linked to ego-modifying effects [fact:8|Psilocybin, a compound found in magic mushrooms, initiates...], and altering the functional connectivity of the claustrum [fact:54|Psilocybin acutely alters the functional connectivity of the...]. Furthermore, it has been shown to calm brain circuits related to pain and mood in the anterior cingulate cortex [fact:2|University of Pennsylvania researchers found that psilocybin can...].\n\nClinical interest in psilocybin focuses on its potential to treat conditions such as major depressive disorder and anxiety in cancer patients [fact:3|Psilocybin, the active ingredient in magic mushrooms, is being investigated for its potential to treat depression and anxiety in cancer patients.], [fact:5|One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when administered with appropriate support.]. Protocols, such as those used at Johns Hopkins University, typically combine limited dosing sessions with preparatory and integrative therapy to help patients process insights and memories [fact:12|The psilocybin clinical trial protocol at Johns Hopkins...], [fact:14|Integrative sessions following psilocybin treatment are designed to...]. Patients like Nora Osowski have reported that these sessions can facilitate profound shifts in priorities and long-term changes in thinking patterns [fact:13|Nora Osowski described her first psilocybin session as...], [fact:17|Osowski stated: "Psilocybin has had an enduring effect...].\n\nBeyond modern clinical applications, psilocybin has a long history of human use in communal and religious rituals [fact:10|Psilocybin, peyote/mescaline, and Ayahuasca are identified as important...], [fact:18|Psychoactive ingredients used in religious rituals include narcotic...]. Some researchers hypothesize that the dietary incorporation of psilocybin may have served an evolutionary function by promoting prosocial behaviors like singing, storytelling, and social bonding, potentially providing homeostatic utility by addressing serotonin depletion [fact:25|The dietary incorporation of psilocybin and its integration...], [fact:26|The interpersonal and prosocial effects of psilocybin likely...], [fact:29|Psilocybin ingestion could have provided homeostatic utility to...]. Despite its therapeutic promise, researchers are also exploring modified versions of psilocin to retain medical benefits while minimizing hallucinogenic side effects [fact:1|Researchers have created modified versions of psilocin, the...].", "confidence": 1.0, "suggested_concepts": [ "Psilocin", "Serotonin receptors", "Ego-dissolution", "Psychedelic-assisted therapy", "Neuroplasticity", "Functional connectivity", "Indole alkaloids", "Johns Hopkins University psychedelic research", "Mystical experience", "Evolutionary psychology of substance use", "Anterior cingulate cortex", "Claustrum", "Integrative psychotherapy", "Pharmacokinetics of psychedelics" ], "relevant_facts": [ 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 25, 26, 27, 28, 29, 54 ] }

Psilocybin is a classic serotonergic psychedelic compound that acts as a pro-drug, metabolizing into the active substance psilocin [fact:17, 18]. Its pharmacological action is primarily mediated through the 5-HT2A serotonin receptor [fact:17, 22, 57]. Research suggests that psilocybin affects brain modularity and connectivity, with acute-challenge studies showing disruptive effects on network function [fact:28, 30, 39]. Neuroimaging studies, including those using fMRI and PET scans, indicate that psilocybin influences brain regions associated with emotional and social processing, such as the amygdala and the medial pre-frontal cortex [fact:21, 25, 26, 47]. Therapeutically, psilocybin is being investigated for its potential to treat psychiatric conditions, including treatment-resistant depression, anxiety in cancer patients, tobacco addiction, and anorexia nervosa [fact:3, 4, 5, 11, 31, 50, 53]. Clinical trials, such as those conducted by Carhart-Harris et al., have examined its efficacy against traditional antidepressants like escitalopram [fact:45]. Proponents suggest that psilocybin-assisted therapy can help individuals suffering from "diseases of despair" by fostering a flexible, associative mode of cognition [fact:54, 57]. Some studies note that mystical-type experiences occasioned by psilocybin correlate with enduring positive changes in psychological functioning, prosocial attitudes, and openness [fact:1, 14, 15, 16]. However, the field also includes critical perspectives, such as researcher skepticism regarding claims that psilocybin "liberates" depressed minds [fact:48]. Beyond modern clinical applications, psilocybin has a historical context; Bernardino de Sahagún documented its use in Aztec rituals, which featured elements reminiscent of group therapy [fact:55]. Evolutionary theories propose that the consumption of psilocybin may have influenced human social evolution by enhancing prosociality and aiding in the development of social bonding mechanisms like music and religion [fact:58, 59]. Despite its potential, psilocybin administration is associated with side effects, including delayed transient headaches and acute adverse reactions [fact:7, 13].

Psilocybin is a psychoactive substance characterized by its structural similarity to the neurotransmitter serotonin and its high safety profile, including a favorable therapeutic index and low toxicity [12, 14, 16, 22]. Research into its effects spans both modern clinical therapeutics and evolutionary hypotheses regarding its role in human development. In contemporary science, psilocybin is recognized for its potential to modulate brain function, including increasing neural signal complexity and functional network integration [47]. It is associated with significant improvements in mood disorders, such as depression and anxiety, and is noted for inducing mystical-type experiences that can lead to enduring, positive shifts in personality traits like Openness and Extraversion [28, 32, 38, 55, 57]. Studies by researchers such as Griffiths et al. and others have documented how these experiences foster altruism, empathy, and interpersonal closeness [30, 36, 56, 59]. From an evolutionary perspective, the "psychedelic instrumentalization model" proposes that the intentional use of psilocybin by early hominins may have provided a survival advantage [8, 13]. By acting as a potential substitute for serotonin during periods of nutrient-linked depletion, psilocybin may have facilitated adaptive stress-coping and socio-cognitive growth [5, 22, 43]. Authors of the paper 'Psychedelics, Sociality, and Human Evolution' suggest this integration into ancient diets and social structures could have created feedback loops that reinforced cooperative behaviors and symbolic cognition, though they caution against oversimplified claims that psilocybin alone drove human evolution [1, 4, 6, 25].

Psilocybin is a psychedelic compound that exerts its primary neurological effects through the activation of serotonin 2A (5-HT2A) receptors classic psychedelics exert primary effects, which are densely expressed throughout the cortex. Research by Kometer et al. (2013) indicates these receptors underlie the compound's impact on alpha oscillations, visual-evoked potentials, and hallucinations activation of serotonin 2A receptors. Beyond sensory effects, psilocybin is associated with biased facial recognition and mood states toward positive emotions psilocybin biases facial recognition and reduced amygdala reactivity reduces threat-induced modulation. In a therapeutic context, psilocybin is classified alongside ketamine as a "psychoplastogen"—an agent that rapidly enhances neuroplasticity act as 'psychoplastogens'. Clinical models for psilocybin-assisted psychotherapy are highly formalized, typically involving three phases: preparation, one or two high-dose sessions in a de-medicalized environment, and post-experience integration Psychedelic-Assisted Psychotherapy (PAP) is generally. These interventions have shown potential in treating depression, anxiety, and alcohol dependence, often producing sustained improvements that persist beyond the presence of the drug in the body rapid improvements in psychiatric conditions. Success is often linked to the quality of the subjective experience, such as "emotional breakthroughs" and mystical encounters psilocybin currently has stronger evidence. While historical use of psilocybin dates back to Tiwanaku shamanism part of the ancient armamentarium, modern research faced significant regulatory hurdles until recent years Scientific American called for. Today, psilocybin is the subject of growing clinical interest, with Australia becoming the first nation to legalize its use for certain mental health conditions legalize psilocybin for mental.

Psilocybin is a psychoactive tryptamine found in various fungi, such as *Psilocybe* spp. utilized by the Mazatec people [5] and *Gymnopilus junonius* used in China [4]. It functions primarily as a 5-HT (serotonin) agonist, with its activation of 5-HT2A receptors leading to significant alterations in sensory perception and cognition [58]. Research suggests psilocybin has a favorable safety profile compared to other substances, with literature reviews indicating low chronic toxicity and a lack of overdose death reports when administered in controlled, supportive environments [6, 12]. Although it can cause adverse physical effects like nausea or dizziness [7] and psychological risks such as anxiety or, in rare cases, prolonged psychosis in predisposed individuals [8, 10], there is no evidence that even exceptional overdoses lead to enduring biological harm [9]. Therapeutically and cognitively, psilocybin is noted for its ability to modulate social cognition and emotional processing. It has been shown to increase empathy [15, 17], shift emotional bias toward positive stimuli [16], and decrease amygdala reactivity to negative affective inputs [19, 22]. These properties have led researchers to investigate its potential in treating conditions such as treatment-resistant depression [18, 50], anxiety in cancer patients [51], and alcohol dependence [49]. Furthermore, studies indicate that psilocybin can induce mystical-type experiences [33], enhance openness [20], and foster creative cognition through both spontaneous insights and improved problem-solving [24, 28, 39, 53]. Beyond clinical applications, the "psychedelic instrumentalization model" proposes that psilocybin may have historically enhanced human adaptability and fitness by stimulating systems related to learning, sociality, and communication [3, 14]. This perspective, supported by theories from figures like Terence McKenna [2], suggests that the substance's effects—including heightened visual acuity and emotional connectivity—may have played a role in hominin evolution [2].

Psilocybin is a psychoactive compound currently being investigated for its therapeutic potential in mental health, particularly for depression and PTSD [44]. It has received breakthrough therapy designation from the FDA [43] and has shown efficacy in various clinical studies, including those focused on treatment-resistant depression [17] and anxiety/depression in cancer patients [18]. Neurobiologically, psilocybin is associated with significant alterations in brain function. Research by Carhart-Harris et al. [32] and Kometer et al. [33] indicates that psilocybin decreases activity in the posterior cingulate cortex (PCC) and the default mode network (DMN). Furthermore, studies suggest it enhances connectivity between brain networks [37] and promotes less constrained, more intercommunicative modes of brain function [39]. While some research has observed that high doses in mice may reduce BrdU-labeled cells [1], other studies suggest that the antidepressant-like effects of psilocybin in mice may function independently of 5-HT2R activation [3]. Subjectively, psilocybin is known for inducing 'mystical-type' experiences [20, 23], characterized by feelings of sacredness, transcendence of time and space, and positive mood changes [25]. These effects have been linked to persisting positive shifts in personality, such as increased openness [27]. In clinical practice, the most common administration model involves one or two high-dose sessions [10], which differs from the 'Montreal model' used for ketamine—a drug that shares some subjective features with psilocybin [7] but utilizes a multi-session protocol [11, 13]. Experts note that the transition of psilocybin from clinical trials to broad clinical care faces challenges similar to those identified in existing psychedelic-assisted therapy models [14, 45].

Psilocybin is a naturally occurring serotonin receptor agonist found in specific mushroom species [psilocybin is a serotonin receptor agonist | 48]. Research into its effects often focuses on its ability to induce mystical-type experiences, which Roland Griffiths reported can yield significant, sustained personal and spiritual meaning [psilocybin can occasion mystical-type experiences | 6]. These experiences, when integrated with spiritual practices, have been linked to enduring improvements in psychological functioning and prosocial attitudes [psilocybin-occasioned mystical experiences | 12]. Neurobiologically, psilocybin is associated with decreased functional segregation and altered network communication, including reduced oscillatory activity in the Default Mode Network [under the influence of psilocybin | 44, 45]. Research by Lebedev et al. and Mason has investigated the link between these neural changes and the experience of ego dissolution [neural correlates of ego-dissolution | 11, 10]. Furthermore, studies suggest psilocybin shifts emotional bias toward positive stimuli by reducing threat processing from the amygdala to the visual cortex [psilocybin produces a shift | 56]. Therapeutically, psilocybin is being evaluated for conditions such as depression, anxiety, tobacco addiction, and obsessive-compulsive disorder [therapeutic applications of psilocybin | 33, 23, 29]. Notably, clinical trials by Ross et al. have demonstrated rapid and sustained symptom reduction in patients with life-threatening cancer [randomized controlled trial | 37, 50]. Beyond mental health, researchers are investigating the use of psilocybin to increase conscious awareness in patients with disorders of consciousness, with virtual simulations suggesting it may promote more flexible and complex brain dynamics [virtual clinical trial | 16, 39, 54]. Comparative research often distinguishes psilocybin from other substances. While LSD and psilocybin share certain characteristics, such as increased brain signal diversity, they differ in their receptor-site activity and the intensity of specific subjective effects [LSD and psilocybin | 3, 59, 42]. Similarly, while ketamine is sometimes discussed alongside psilocybin in psychedelic treatment models, it is noted for a shorter duration of action and higher scores in "disembodiment" [ketamine's subjective effects | 22, 60].

Psilocybin is a psychedelic tryptamine frequently studied as a prototypical serotonin 2A receptor agonist, though psychedelic models extend to other substances like MDMA and ketamine some experts define 'psychedelic' as 5-HT2A agonists like psilocybin. Research on its effects dates to Leary, Litwin, and Metzner's 1963 study of reactions in supportive settings Leary et al. documented psilocybin effects, with modern work including Carter et al.'s 2007 findings linking it to binocular rivalry, attention, and arousal Carter et al. on psilocybin and rivalry. Neural imaging reveals increased MEG signal diversity at psychoactive doses, comparable to LSD and ketamine Schartner et al. on MEG diversity, but meta-analyses by Yaden, Johnson, Griffiths et al. note heterogeneous neural fingerprints for psilocybin, DMT, and LSD, urging standardization heterogeneous neural fingerprints literature. Clinically, it's explored in psychotherapy Frontiers in Psychology on psychedelic psychotherapy and end-of-life trials, where one participant suicided post-1mg dose despite no general suicidality reports (Consul et al., Taylor & Francis) subtherapeutic dose suicide case. The Montreal ketamine model equates six IV sessions to two or twelve psilocybin doses in altered consciousness time (Frontiers in Psychiatry) ketamine vs. two psilocybin doses. A 2014 Scientific American editorial advocated lifting research bans on psilocybin amid stagnant mental health progress (UC Berkeley Center) Scientific American on research bans, while tryptamine reviews show 18% of studies focus on it (Springer) tryptamine studies proportion. Recent scales by Stocker et al. (2024) assess its mystical and distressing experiences alongside LSD psychedelic experience scale revival.

Psilocybin is a psychoactive substance frequently classified as a psychedelic, with some experts specifically defining the term based on its action as a serotonin 2A receptor agonist psychedelic definition as serotonin agonists. Scientific inquiry into psilocybin has historically faced regulatory barriers, leading to calls from publications like *Scientific American* to end bans on psychedelic research due to a perceived lack of progress in mental health treatments Scientific American editorial on research bans. Research on psilocybin involves various methodologies, ranging from documenting its effects in controlled, supportive environments supportive environment research to examining its physiological and neurological impacts. Studies have linked psilocybin to changes in binocular rivalry switch rates, attention, and arousal psilocybin links to attention, as well as increased spontaneous MEG signal diversity MEG signal diversity findings. While meta-analyses suggest that psilocybin, along with LSD and DMT, possesses specific, non-linear neural fingerprints neural fingerprints of psychedelics, researchers note that this literature is characterized by high heterogeneity and bias, necessitating more standardized procedures need for standardized research. In clinical contexts, psilocybin is often compared to other psychoactive substances like ketamine, particularly regarding the duration of altered states of consciousness ketamine and psilocybin duration. Despite its use in clinical trials, safety remains a focus, including the study of an experiential spectrum that encompasses mystical and distressing elements experiential spectrum of psilocybin. Clinical outcomes vary; for instance, while treatment-emergent suicidality has not been typically reported, one instance of suicide occurred in a trial participant following a subtherapeutic dose clinical trial safety concerns.

Psilocybin, a serotonergic psychedelic and 5-HT2A agonist, induces profound altered states of consciousness, mystical experiences, and changes in brain dynamics, as extensively studied in healthy volunteers and clinical populations. Researchers Tylš, Páleníček, and Horáček summarized knowledge and perspectives (2014) provided a summary…) and examined neurobiology for therapeutics (2016) examined the neurobiology…), while Roland Griffiths, Matthew Johnson, and colleagues validated mystical experience questionnaire (2015) validated the revised…) and documented dose-related persisting effects (various). Neuroimaging reveals increased MEG signal diversity (Schartner et al. 2017) reported that psychoactive doses…), reduced oscillatory power (Muthukumaraswamy et al. 2013) found that psilocybin caused…), and dynamic hyperconnectivity linked to oceanic boundlessness (Mortaheb et al. 2024) found that dynamic functional…). Therapeutic potential spans treatment-resistant depression (Roseman et al. 2017) found that the quality…), tobacco addiction pilot study (Johnson), end-of-life distress, and simulated benefits for disorders of consciousness (Alnagger et al.). Compared to LSD and ketamine, psilocybin shows distinct subjective effects and scales (various), with higher mystical ratings but lower visionary restructuralization.